


ANDA 75-382

**OFFICE OF GENERIC DRUGS**

Food and Drug Administration
HFD-600, Metro Park North II
7500 Standish Place, Room 150
Rockville, MD 20855-2773
Fax: (301-594-0180)

FAX TRANSMISSION COVER SHEET

TO: APPLICANT: Carlsbad Technology Inc.

PHONE: 760-431-8284

ATTN: Simon Hsu

FAX: 760-431-7507

FROM: Mark Anderson

PROJECT MANAGER (301) 827-5849

Dear Sir:

This facsimile is in reference to your abbreviated new drug application for Acyclovir Tablets USP, 400 mg and 800 mg.

We are pleased to inform you that this application is APPROVED!

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, OR PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If received by someone other than the addressee or a person authorized to deliver this document to the addressee, you are hereby notified that any disclosure, dissemination, copying, or other action to the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us by mail at the above address.

X:\new\ogdadmin\macro\faxapp.ltm



DEPARTMENT OF HEALTH & HUMAN SERVICES

NO. 469 Pg 2

ANDA 75-382

Food and Drug Administration
Rockville MD 20857

APR 30 1999

Carlsbad Technology Inc.
Attention: Simon Hsu
5923 Balfour Court
Carlsbad, CA 92008

Dear Sir:

This is in reference to your abbreviated new drug application dated May 7, 1998, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Acyclovir Tablets USP, 400 mg and 800 mg.

Reference is also made to your amendments dated August 20, and November 19, 1998; and February 22, and April 26, 1999.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Acyclovir Tablets USP, 400 mg and 800 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Zovirax® Tablets 400 mg and 800 mg, respectively, of Glaxo Wellcome, Inc.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.


Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

Page 2

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

A handwritten signature in dark ink, appearing to read "D. L. Sporn", written in a cursive style.

Douglas L. Sporn

Director

Office of Generic Drugs

Center for Drug Evaluation and Research